ZA991569B - Derivatives of GLP-1 analogs. - Google Patents
Derivatives of GLP-1 analogs.Info
- Publication number
- ZA991569B ZA991569B ZA9901569A ZA991569A ZA991569B ZA 991569 B ZA991569 B ZA 991569B ZA 9901569 A ZA9901569 A ZA 9901569A ZA 991569 A ZA991569 A ZA 991569A ZA 991569 B ZA991569 B ZA 991569B
- Authority
- ZA
- South Africa
- Prior art keywords
- glp
- analogs
- derivatives
- present
- action
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Dowels (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK26898 | 1998-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA991569B true ZA991569B (en) | 1999-08-27 |
Family
ID=8091634
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9901569A ZA991569B (en) | 1998-02-27 | 1999-02-26 | Derivatives of GLP-1 analogs. |
ZA9901570A ZA991570B (en) | 1998-02-27 | 1999-02-26 | Partially structured micellar-like GLP-1 aggregates. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9901570A ZA991570B (en) | 1998-02-27 | 1999-02-26 | Partially structured micellar-like GLP-1 aggregates. |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1060191B1 (xx) |
JP (1) | JP2002512175A (xx) |
AT (1) | ATE466027T1 (xx) |
AU (1) | AU2610699A (xx) |
DE (1) | DE69942306D1 (xx) |
WO (1) | WO1999043706A1 (xx) |
ZA (2) | ZA991569B (xx) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69911975T2 (de) | 1998-07-31 | 2004-09-09 | Novo Nordisk A/S | In-vitro stimulation von beta zellen vermehrung |
EP1634605A3 (en) | 2000-03-08 | 2006-10-11 | Novo Nordisk A/S | treatment of dyslipidemia in a patient having type 2 diabetes |
EP1294757B1 (en) | 2000-06-16 | 2006-11-22 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
WO2002043709A1 (fr) | 2000-12-01 | 2002-06-06 | Takeda Chemical Industries, Ltd. | Procede de production d'une preparation contenant une substance bioactive |
CA2716959A1 (en) | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
WO2002069994A2 (en) | 2001-03-07 | 2002-09-12 | Novo Nordisk A/S | Combined use of derivatives of glp-1 analogs and ppar ligands |
ATE382057T1 (de) * | 2001-06-28 | 2008-01-15 | Novo Nordisk As | Stabile formulierung von modifiziertem glp-1 |
CA2458371A1 (en) | 2001-08-23 | 2003-03-06 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
US7238663B2 (en) * | 2001-08-28 | 2007-07-03 | Eli Lilly And Company | Pre-mixes of GLP-1 and basal insulin |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
MXPA04003569A (es) * | 2001-10-19 | 2004-07-23 | Lilly Co Eli | Mezclas bifasicas de glp-1 e insulina. |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003059378A2 (en) | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
EP1585959A4 (en) * | 2002-01-08 | 2007-11-14 | Lilly Co Eli | PEPTIDE-1 ANALOGUES OF EXTENSION GLUCAGON TYPE |
US20050148497A1 (en) | 2002-02-20 | 2005-07-07 | Khan Mohammed A. | Method for administering glp-1 molecules |
KR20050049525A (ko) * | 2002-10-11 | 2005-05-25 | 가부시키가이샤산와카가쿠켄큐쇼 | Glp-1 유도체 및 그의 경점막 흡수형 제제 |
ATE502665T1 (de) | 2003-02-04 | 2011-04-15 | Novo Nordisk As | Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung |
ES2336563T3 (es) * | 2003-02-19 | 2010-04-14 | Ipsen Pharma | Analogos de glp-1. |
SI1605897T1 (sl) * | 2003-03-19 | 2012-11-30 | Lilly Co Eli | Polietilen glikol povezane GLP spojine |
ES2383752T3 (es) | 2003-05-15 | 2012-06-26 | Trustees Of Tufts College | Analogos estables de GLP-1 |
PL1633391T3 (pl) | 2003-06-03 | 2012-03-30 | Novo Nordisk As | Stabilizowane farmaceutycznie kompozycje peptydowe |
ATE529126T1 (de) | 2003-06-03 | 2011-11-15 | Novo Nordisk As | Stabilisierte pharmazeutische peptid zusammensetzungen |
JP4936884B2 (ja) | 2003-06-03 | 2012-05-23 | ノボ・ノルデイスク・エー/エス | 安定化された薬学的ペプチド組成物 |
US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
HUE038395T2 (hu) | 2003-11-20 | 2018-10-29 | Novo Nordisk As | Propilén-glikol tartalmú peptidkészítmények, amelyek elõállításra és injekciós eszközökben történõ alkalmazásra optimálisak |
JP4865565B2 (ja) | 2003-12-09 | 2012-02-01 | ノヴォ ノルディスク アー/エス | Glp−1アゴニストを用いた食物選択の制御 |
CA2551039C (en) * | 2003-12-16 | 2013-01-29 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Analogues of glp-1 |
DE602004026113D1 (de) | 2003-12-18 | 2010-04-29 | Novo Nordisk As | Glp-1-verbindungen |
BRPI0506662B8 (pt) | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
JP2007537149A (ja) | 2004-01-08 | 2007-12-20 | セラテクノロジーズ インコーポレイテッド | 長時間作用性のグルカゴン様ペプチド−1類似体 |
ES2642214T3 (es) | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
JP2008501765A (ja) | 2004-06-11 | 2008-01-24 | ノボ ノルディスク アクティーゼルスカブ | Glp−1アゴニストを用いた薬剤誘発性肥満の中和 |
JP4965446B2 (ja) | 2004-08-31 | 2012-07-04 | ノヴォ ノルディスク アー/エス | ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス(ヒドロキシメチル)アミノメタンの使用 |
JP5107713B2 (ja) | 2004-10-07 | 2012-12-26 | ノヴォ ノルディスク アー/エス | 遅延性のエキセンディン−4化合物 |
EP1799710A2 (en) | 2004-10-07 | 2007-06-27 | Novo Nordisk A/S | Protracted glp-1 compounds |
AU2005303777B2 (en) | 2004-11-12 | 2010-12-16 | Novo Nordisk A/S | Stable formulations of insulinotropic peptides |
WO2006058923A1 (en) | 2004-12-03 | 2006-06-08 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
US7884210B2 (en) | 2005-07-14 | 2011-02-08 | Novo Nordisk A/S | Ureido-thiazole glucokinase activators |
JP5312054B2 (ja) | 2006-03-15 | 2013-10-09 | ノボ・ノルデイスク・エー/エス | アミリンとインスリンの混合物 |
JP5226008B2 (ja) | 2007-01-11 | 2013-07-03 | ノボ・ノルデイスク・エー/エス | ウレアグルコキナーゼアクチベーター |
CN101743252A (zh) | 2007-07-16 | 2010-06-16 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、peg化的胰岛素类似物 |
PT2597103T (pt) | 2007-11-16 | 2017-02-08 | Novo Nordisk As | Composições farmacêuticas contendo insulina e um péptido insulinotrófico |
PL2254906T3 (pl) | 2008-03-18 | 2017-04-28 | Novo Nordisk A/S | Stabilizowane względem proteaz, acylowane analogi insuliny |
EP2344519B1 (en) | 2008-11-07 | 2016-09-28 | The General Hospital Corporation | C-terminal fragments of glucagon-like peptide-1 (glp-1) |
AU2010312655A1 (en) | 2009-10-30 | 2012-05-03 | Glytech, Inc. | Glycosylated form of antigenic GLP-1 analogue |
CN102791731B (zh) * | 2009-12-16 | 2016-04-20 | 诺沃—诺迪斯克有限公司 | Glp-1类似物和衍生物 |
WO2011123943A1 (en) | 2010-04-09 | 2011-10-13 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
CA2793715A1 (en) | 2010-04-30 | 2011-11-03 | Sanwa Kagaku Kenkyusho Co., Ltd. | Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability |
US9040481B2 (en) | 2010-11-02 | 2015-05-26 | The General Hospital Corporation | Methods for treating steatotic disease |
JP6039569B2 (ja) | 2010-11-09 | 2016-12-07 | ノヴォ ノルディスク アー/エス | 二重アシル化されたglp−1誘導体 |
RS56998B1 (sr) | 2010-12-16 | 2018-05-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
KR102093463B1 (ko) * | 2011-04-12 | 2020-03-26 | 노보 노르디스크 에이/에스 | 이중 아실화된 glp-1 유도체 |
WO2012140117A1 (en) | 2011-04-12 | 2012-10-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
EP2729157B1 (en) | 2011-07-06 | 2019-01-16 | The General Hospital Corporation | A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment |
CN104039822A (zh) * | 2011-09-06 | 2014-09-10 | 诺沃—诺迪斯克有限公司 | Glp-1衍生物 |
CN104244981A (zh) | 2011-12-09 | 2014-12-24 | 诺和诺德A/S | Glp-1激动剂 |
CN104203221A (zh) | 2012-03-22 | 2014-12-10 | 诺和诺德A/S(股份有限公司) | 包含递送剂的组合物及其制备 |
WO2013139694A1 (en) | 2012-03-22 | 2013-09-26 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
HUE042757T2 (hu) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Szállító szert tartalmazó készítmények és elõállításuk |
EP2846823B1 (en) | 2012-05-08 | 2019-12-04 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
WO2013167455A1 (en) | 2012-05-08 | 2013-11-14 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
US20150157619A1 (en) | 2012-07-10 | 2015-06-11 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation for injection |
WO2014060472A1 (en) | 2012-10-17 | 2014-04-24 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
BR112015030948A2 (pt) | 2013-06-20 | 2017-09-19 | Novo Nordisk As | Derivados de glp-1 e usos dos mesmos |
BR112015032875A2 (pt) * | 2013-07-04 | 2017-11-07 | Novo Nordisk As | derivados de peptídeos do tipo glp-1, e usos dos mesmos |
JP6768515B2 (ja) | 2014-04-07 | 2020-10-14 | ノヴォ ノルディスク アー/エス | 二重アシル化glp−1化合物 |
ES2630106T3 (es) | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
EP3226906B1 (en) * | 2014-11-27 | 2019-06-12 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
WO2016097108A1 (en) | 2014-12-17 | 2016-06-23 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
AU2016335287A1 (en) | 2015-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
JP2020510028A (ja) * | 2017-03-08 | 2020-04-02 | インターシア セラピューティクス,インコーポレイティド | 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法 |
TWI762706B (zh) | 2017-08-24 | 2022-05-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1組成物及其用途 |
KR102647171B1 (ko) | 2018-02-02 | 2024-03-15 | 노보 노르디스크 에이/에스 | Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물 |
HUE060135T2 (hu) | 2018-04-05 | 2023-02-28 | Sun Pharmaceutical Ind Ltd | Új GLP-1 analógok |
JP7442823B2 (ja) | 2018-04-06 | 2024-03-05 | シプルメット・ゲーエムベーハー | 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物 |
TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
EP3938037A1 (en) | 2019-03-15 | 2022-01-19 | Diet4Life ApS | Combination of dietary peptides |
BR112022013795A2 (pt) | 2020-02-18 | 2022-09-13 | Novo Nordisk As | Composição farmacêutica líquida, e, kit |
WO2021219710A1 (en) | 2020-04-29 | 2021-11-04 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
EP4210680A1 (en) | 2020-09-07 | 2023-07-19 | Cyprumed GmbH | Improved pharmaceutical formulations of glp-1 receptor agonists |
CN115925994B (zh) | 2020-09-30 | 2023-09-22 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
IL302159A (en) * | 2020-11-06 | 2023-06-01 | Novo Nordisk As | GLP-1 drug inhibitors and uses thereof |
BR112023012422A2 (pt) | 2021-01-24 | 2023-12-12 | Michael David Forrest | Inibidores da atp sintase - usos cosmético e terapêutico |
EP4281039A2 (en) | 2021-01-25 | 2023-11-29 | Mylan Ireland Limited | Pharmaceutical glp peptide compositions and methods of preparation thereof |
WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
WO2024141760A1 (en) | 2022-12-30 | 2024-07-04 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
DE3750402T3 (de) | 1986-05-05 | 1997-04-10 | Gen Hospital Corp | Insulinotropes hormon. |
NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
ATE193541T1 (de) | 1989-03-20 | 2000-06-15 | Gen Hospital Corp | Insulinotropes hormon |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
DK36492D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5869602A (en) * | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
-
1999
- 1999-02-25 JP JP2000533456A patent/JP2002512175A/ja not_active Withdrawn
- 1999-02-25 WO PCT/DK1999/000082 patent/WO1999043706A1/en active Application Filing
- 1999-02-25 EP EP99906076A patent/EP1060191B1/en not_active Expired - Lifetime
- 1999-02-25 DE DE69942306T patent/DE69942306D1/de not_active Expired - Lifetime
- 1999-02-25 AU AU26106/99A patent/AU2610699A/en not_active Abandoned
- 1999-02-25 AT AT99906076T patent/ATE466027T1/de not_active IP Right Cessation
- 1999-02-26 ZA ZA9901569A patent/ZA991569B/xx unknown
- 1999-02-26 ZA ZA9901570A patent/ZA991570B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO1999043706A1 (en) | 1999-09-02 |
ZA991570B (en) | 1999-09-02 |
ATE466027T1 (de) | 2010-05-15 |
JP2002512175A (ja) | 2002-04-23 |
EP1060191B1 (en) | 2010-04-28 |
AU2610699A (en) | 1999-09-15 |
EP1060191A1 (en) | 2000-12-20 |
DE69942306D1 (de) | 2010-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA991569B (en) | Derivatives of GLP-1 analogs. | |
WO1999002514A3 (en) | Epothilone derivatives | |
BG105967A (en) | C(7) ester substituted taxanes and their use as antitumor agents | |
IL137465A0 (en) | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | |
EG24968A (en) | Prodrugs of 4-phenyl-pyridine derivatives. | |
BG104247A (en) | Resorcinol derivatives | |
HN1998000036A (es) | Compuesto de pirazina | |
DE69224712D1 (de) | Verschleissfeste, flammhemmende Zusammensetzungen | |
HK1040397A1 (en) | substituted benzopyran analogs for the treatment of inflammation. | |
IL135590A0 (en) | A process for the reduction of oxiranyl epothilones to olefinic epothilones | |
MY132129A (en) | Polyarylcarboxamides useful as lipid lowering agents | |
MX9605206A (es) | 1alfa,26-dihidroxi-d-homo-vitamina d3. | |
IL141328A0 (en) | Pantoprazole magnesium dihydrat | |
MX9804588A (es) | Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel. | |
ZA976242B (en) | Illudin analogs useful as antitumor agents. | |
HK1045990A1 (en) | Novel derivatives and analogues of galanthamin. | |
HUP0202157A2 (en) | Novel vitamin d3 analogs | |
HK1048302A1 (zh) | ***素衍生物 | |
UA66866C2 (uk) | Синтез морфолінових похідних | |
BG106016A (en) | Resorcinol derivatives | |
AU2001296775A1 (en) | Triptycene analogs | |
EA200100564A1 (ru) | Препарат, снижающий выделение пролактина | |
BG105964A (en) | C(10) carbonate substituted taxanes and their use as antitumor agents | |
PL352063A1 (en) | Derivatives (of benzodioxane, benzophurane or benzopyrane) substituted by pyrolydinylene, piperydinylene or homopiperydinylene | |
PL352112A1 (en) | Derivatives (of benzodioxane, benzophurane or benzopyrane) substituted by aminoalkil |